enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. House lawmakers slam pharmacy middlemen over sky-high drug prices

    www.aol.com/news/house-lawmakers-slam-pharmacy...

    “On one hand we have PBMs claiming to reduce prescription drug prices, and on the other hand we have the Federal Trade Commission, we have major media outlets like The New York Times and we have ...

  3. Pharma companies less concerned after hearing from US on ...

    www.aol.com/news/pharma-companies-less-concerned...

    By Patrick Wingrove and Michael Erman (Reuters) - Four pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare program said they do not expect a significant ...

  4. Tesla downgraded to Sell at UBS; valuation premium 'too ... - AOL

    www.aol.com/finance/tesla-downgraded-sell-ubs...

    Hence the Sell rating on Tesla, and $197 price target, which the UBS team believes accurately values Tesla, its core auto business, and its other endeavors. Spak acknowledges the bank could be ...

  5. Specialty drugs in the United States - Wikipedia

    en.wikipedia.org/wiki/Specialty_drugs_in_the...

    By 2012 the price of a vial of Acthar was $28,400. [90] and was considered to be one of the world's most expensive drugs in 2013. By 2014 the price of Gilead's specialty drug for hepatitis C, Sovaldi or sofosbuvir, was $84,000 to $168,000 for a course of treatment in the U.S., £35,000 in the UK for 12 weeks. [92]

  6. Drug Price Competition and Patent Term Restoration Act

    en.wikipedia.org/wiki/Drug_Price_Competition_and...

    e. The Drug Price Competition and Patent Term Restoration Act (Public Law 98-417), informally known as the Hatch-Waxman Act, is a 1984 United States federal law that established the modern system of generic drug regulation in the United States. The Act's two main goals are to facilitate entry of generic drugs into the market and to compensate ...

  7. Prescription Drug User Fee Act - Wikipedia

    en.wikipedia.org/wiki/Prescription_Drug_User_Fee_Act

    Signed into law by President George H. W. Bush on October 29, 1992. The Prescription Drug User Fee Act ( PDUFA) was a law passed by the United States Congress in 1992 which allowed the Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the new drug approval process. The Act provided that the FDA was entitled to ...

  8. Column: Pharmacy middlemen claim to keep prescription prices ...

    www.aol.com/news/column-pharmacy-middlemen-claim...

    Along with Humana, the fourth-ranked PBM with a market share of 7%, those conglomerates produced combined revenue of $456 billion in 2016, 14% of national health spending.

  9. Pharmaceutical marketing - Wikipedia

    en.wikipedia.org/wiki/Pharmaceutical_marketing

    Pharmaceutical marketing is a branch of marketing science and practice focused on the communication, differential positioning and commercialization of pharmaceutical products, like specialist drugs, biotech drugs and over-the-counter drugs. By extension, this definition is sometimes also used for marketing practices applied to nutraceuticals ...